DiaSorin S.p.A.
DiaSorin S.p.A. (DSRLF) Stock Overview
Explore DiaSorin S.p.A.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
5.8B
P/E Ratio
33.28
EPS (TTM)
$4.03
ROE
0.09%
DSRLF Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of DiaSorin S.p.A. (DSRLF) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $101.30.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 33.28 and a market capitalization of 5.8B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Analyst Recommendations
Price Targets
Company Profile
DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.
Carlo Rosa
3,249
Via Crescentino snc, Saluggia, VC
2009